Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
12 clinical trials · Condition
◉ Watch Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
| Record | Firm | Date |
|---|---|---|
| Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT04285268) | Rutgers, The State University of New Jersey | 2020-05-06 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672) | National Cancer Institute (NCI) | 2018-12-21 |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT03103971) | Fred Hutchinson Cancer Center | 2017-11-03 |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (NCT03136146) | M.D. Anderson Cancer Center | 2017-08-09 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012) | National Cancer Institute (NCI) | 2013-07-17 |
Track Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements automatically
Every clearance here is in the API, with alerts when new ones post.